"Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD₅₀ = 7.8 mg/kg (orally in mice)."@en . . . "3.5 to 5 days"@en . . "12\u03B2-hydroxydigitoxin"@en . . . "# Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8094898 # Doering W, Konig E, Sturm W: [Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)] Z Kardiol. 1977 Mar;66(3):121-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/857452 # Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6665298 # Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15554746"@en . "Lanadicor"@en . . . "25%"@en . . "Digossina"@en . . . . . "Digoxin"@en . . . . . . . . . . . . . . . . . . . . . . . . "Avoid excess salt/sodium unless otherwise instructed by your physician."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Humans and other mammals"@en . . . . "Digazolan"@en . . . . . . . . "Digoxin"@en . . . . . . . . . . . . . "Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication."@en . "4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one"@en . . . "Avoid salt substitutes containing potassium."@en . . . . . . . . . . "12beta-Hydroxydigitoxin"@en . . . . . . . . . . . . . " "@en . . . . . "20830-75-5"@en . "Avoid bran and high fiber foods within 2 hours of taking this medication."@en . "Limit garlic, ginger, gingko, and horse chestnut."@en . "Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential."@en . "Following intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine."@en . "Avoid avocado."@en . . "A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)"@en . "Digoxina"@en . . . "Wolfgang Voigtlander, Fritz Kaiser, Wolfgang Schaumann, Kurt Stach, \"Preparation of C22-alkyl derivative of digoxin.\" U.S. Patent US3981862, issued October, 1972."@en . . . . . . . . . . . . . . . . . . . . . . . . . . "approved"@en . . . . "Absorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets)."@en . . . . . . "Digoxinum"@en . "Digoxine"@en . "For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure."@en .